Keywords: AstraZeneca, Seroquel, Antipsychotice, FDA injunction, USA, Court decision,
US court turns down AstraZeneca FDA injunction; Teva debuts generic Seroquel in UK
Article | 26 March 2012
In another setback for Anglo-Swedish drug major AstraZeneca in its fight to delay generic competition for its blockbuster antipsychotic Seroquel ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
